Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Upstream Bio, Inc.NASDAQ: UPB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$40.54M, compared with -$27.23M a year earlier. Trailing-twelve-month EBITDA was -$156.57M.
Context
- EBITDA amounted to 5019.4% of revenue in FY2025, up 2373.2 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$167.26M (-16.8%) for the fiscal year ending Dec 2026, a step up from the -128.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$40.54M+4.4% QoQ
- Last fiscal yearDec 2025
- -$143.26M-128.4% YoY
- LTMMar 2026
- -$156.57M-98.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -48.9% | -2.0% | +46.9 pp |
| 1 year | -128.4% | -16.8% | +111.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (143.26M) USD
- Year-over-year change
- -128.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143.26M) | -128.4% |
| FY2024 | 2024-12-31 | (62.72M) | -206.3% |
| FY2023 | 2023-12-31 | (20.48M) | +14.2% |
| FY2022 | 2022-12-31 | (23.86M) | — |
EBITDA vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -98.0% is the 8th highest of 10, against a peer median of -15.5%.
- EBITDA amounts to 4713.1% of revenue for UPB, versus a peer median of 276.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$42.13M USD | -107.6% | — | 7.1% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | -$156.57M USD | -98.0% | — | 4713.1% |
| LTM Sep 2026 | -$160.97M USD | -7.8% | — | — | |
| LTM Mar 2026 | -$162.5M USD | +50.0% | — | 74.8% | |
| LTM Mar 2026 | -$174.59M USD | -68.4% | — | 243.2% | |
| LTM Sep 2026 | -€184.94M EUR | -15.5% | — | — | |
| LTM Sep 2026 | -$280.09M USD | -70.6% | — | 309.5% | |
| LTM Jun 2026 | -$283.83M USD | +7.4% | — | 2742.3% | |
| LTM Mar 2026 | -$384.61M USD | +25.4% | — | 581.9% | |
| LTM Mar 2026 | -$408.44M USD | -151.5% | — | — | |
| Peer median (excluding UPB) | — | -15.5% | — | 276.3% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.